They further used these seven miRNAs to construct a serum miRNAs signature that predicts trastuzumab response and found that miR-135b, miR-200b, and miR-29a are upregulated, whereas miR-224 is significantly downregulated in the plasma of the HER-2 enriched BC patients that do not benefit from trastuzumab [96]. Here, ERBB2 is linked to breast cancer.